Radhika Muzumdar, MD

Her research is focused on GH, insulin-like growth factors and their binding partners, and a novel mitochondria-associated peptide called humanin on glucose homeostasis, energy metabolism, cardiovascular health, and aging. Her lab is also studying the link between tumor suppressor gene AIM 2 and obesity, as well as the role of novel acyl dehydrogensase enzyme (ACAD 10) on glucose/lipid metabolism and mitochondrial function. Dr. Muzumdar’s laboratory utilizes relevant murine models, molecular genetic approaches and in vitro biochemical assays to examine novel regulators of energy and glucose homeostasis.  She is on several national and international study sections, including the NIH, AFAR research council, Binational Israel foundation, Israeli Science Foundation, Marsden Fund (New Zealand), and Wellcome Trust UK. She serves as a standing member on the NIA/ASG study section and on AFAR’s National Scientific Advisory Council. Dr. Muzumdar is the principal investigator of the Research Training in Pediatric Endocrinology program (T32). The goal of this T32 training grant is to provide state-of-the-art training in the molecular, cellular, physiologic, genetic, and biochemical aspects of pediatric endocrinology to ensure that the physician-scientists who graduate from this program are well prepared for productive academic careers in translational research related to pediatric endocrinology. She is an active member of the Pediatric Endocrine Society (PES) and is Chair of the Research advisory committee of PES.